Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/29235
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAnderson P.en
dc.contributor.authorGrills N.en
dc.contributor.authorThomas M.en
dc.contributor.authorWong C.C.en
dc.date.accessioned2021-05-14T09:52:16Zen
dc.date.available2021-05-14T09:52:16Zen
dc.date.copyright2020en
dc.date.created20200603en
dc.date.issued2020-06-03en
dc.identifier.citationBMJ Open. 10 (5) (no pagination), 2020. Article Number: e032829. Date of Publication: 18 May 2020.en
dc.identifier.issn2044-6055 (electronic)en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/29235en
dc.description.abstractIntroduction Current evidence indicates an alarming increase in topical steroid (TS) misuse in India. Data regarding the magnitude and characteristics of this problem in rural India, where 68% of the population resides, are insufficient. This study analyses the magnitude, causes, characteristics and consequences of TS misuse in rural India. It also examines the association between TS misuse and patients' perception of skin disease. Methods A mixed-method observational study was conducted among the attendees of the dermatology outpatient department in a rural North Indian hospital. Those with a history of TS misuse were analysed for behaviour patterns and outcome. Results Out of 723 patients, 213 (29.2%) misused TS. Clobetasol propionate (58.2%) was most commonly misused. Seventy brands of inappropriate fixed drug combination steroid creams were recovered from the patients. Pharmacists and local healers together contributed to 78% of the sources for steroid misuse. Almost 58% of participants perceived their skin conditions to be allergic reactions to food, when in fact 70.1% were tinea, 10% scabies and 9% acne. Eighty per cent of the respondents having tinea had tinea incognito and 97% had extensive lesions. Eighty-five per cent of the participants with scabies had atypical lesions and 80% with acne had steroid rosacea or aggravation of acne. The median expenditure incurred in purchasing these potentially harmful steroid creams was Rs 1000 (US$14.1, equivalent to 3 days' wages of a labourer). Conclusion Steroid misuse is a problem of epidemic proportion in rural India. This practice is changing the profile of many common and infective skin conditions, which portends diagnostic dilemmas and therapeutic challenges for clinicians. Misconceptions about skin disease drive the public to seek a quick fixes' from non-allopathic providers who have unrestricted access to potent steroids. There is an urgent need to tighten regulatory controls over the manufacturing, sale and prescription of irrational TS combinations.Copyright © © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.en
dc.languageEnglishen
dc.languageenen
dc.publisherBMJ Publishing Group (E-mail: subscriptions@bmjgroup.com)en
dc.relation.ispartofBMJ Openen
dc.subject.meshfood allergy-
dc.subject.meshhypertension-
dc.subject.meshIndia-
dc.subject.meshmoon face-
dc.subject.meshoutpatient department-
dc.subject.meshpapule-
dc.subject.meshperception-
dc.subject.meshpharmacist-
dc.subject.meshprescription-
dc.subject.meshrosacea-
dc.subject.meshrural area-
dc.subject.meshscabies-
dc.subject.meshskin disease-
dc.subject.meshstria-
dc.subject.meshtinea-
dc.subject.meshamiton-
dc.subject.meshbeclometasone-
dc.subject.meshbeclometasone/tp [Topical Drug Administration]-
dc.subject.meshbeclometasone dipropionate-
dc.subject.meshbetamethasone-
dc.subject.meshbetamethasone/tp [Topical Drug Administration]-
dc.subject.meshbetamethasone valerate-
dc.subject.meshchlorocresol-
dc.subject.meshfluocinolone-
dc.subject.meshfluocinolone/tp [Topical Drug Administration]-
dc.subject.meshfluocinonide-
dc.subject.meshgentamicin-
dc.subject.meshketoconazole-
dc.subject.meshmiconazole-
dc.subject.meshmometasone furoate-
dc.subject.meshmometasone furoate/tp [Topical Drug Administration]-
dc.subject.meshneomycin-
dc.subject.meshofloxacin-
dc.subject.meshornidazole-
dc.subject.meshsalicylic acid-
dc.subject.meshsteroid [Adverse Drug Reaction]-
dc.subject.meshsteroid [Oral Drug Administration]-
dc.subject.meshsteroid/pe [Pharmacoeconomics]-
dc.subject.meshsteroid-
dc.subject.meshsteroid/tp [Topical Drug Administration]-
dc.subject.meshterbinafine-
dc.subject.meshtolnaftate-
dc.subject.meshadoderm mn-
dc.subject.meshaluderm-
dc.subject.meshamitone 5-
dc.subject.meshbetamil-
dc.subject.meshbetnovate n-
dc.subject.meshbifine plus-
dc.subject.meshcandid 3d-
dc.subject.meshcandid b-
dc.subject.meshcanditas bg-
dc.subject.meshcastor nf-
dc.subject.meshcbn-
dc.subject.meshceflox cf-
dc.subject.meshcipro cf-
dc.subject.meshclobenate gm-
dc.subject.meshclobeta gm-
dc.subject.meshclobezine cm-
dc.subject.meshclobriv mg-
dc.subject.meshclorap s-
dc.subject.meshclostar gm-
dc.subject.meshclotebate gm-
dc.subject.meshcosvate gm-
dc.subject.meshdermacin k 5-
dc.subject.meshdermek tc-
dc.subject.meshdermiford-
dc.subject.meshdermiford k 5-
dc.subject.meshdermifrench kt-
dc.subject.meshdermikem oc-
dc.subject.meshdermikemoc-
dc.subject.meshevzole-
dc.subject.meshflucort h-
dc.subject.meshfourderm-
dc.subject.meshiobate-
dc.subject.meshlaboderm oc-
dc.subject.meshlobate gm-
dc.subject.meshlozivate-
dc.subject.meshlozivate mf-
dc.subject.meshlucobet gm-
dc.subject.meshlupiderm gm-
dc.subject.meshmedisalic-
dc.subject.meshneo clobenate gm-
dc.subject.meshnikderm plus-
dc.subject.meshnuforce gm-
dc.subject.mesholtef nf-
dc.subject.meshonabet b-
dc.subject.meshonflox tc-
dc.subject.meshorkaderm-
dc.subject.meshorkid 4-
dc.subject.meshorniderm-
dc.subject.meshpanderm plus-
dc.subject.meshpardum plus-
dc.subject.meshquadriderm-
dc.subject.meshquadriderm rf-
dc.subject.meshring out plus-
dc.subject.meshsarvocin ct-
dc.subject.meshsertamide b-
dc.subject.meshsoltex-
dc.subject.meshsure kt-
dc.subject.meshsurfaz sn-
dc.subject.meshtecderm kt-
dc.subject.meshterbicad-
dc.subject.meshterbinaforce plus-
dc.subject.meshterderm plus-
dc.subject.meshterogood-
dc.subject.meshtocoderm plus-
dc.subject.meshtotalderm plus-
dc.subject.meshunikderm-
dc.subject.meshzenoderm-
dc.subject.meshzincodem gm-
dc.subject.meshzole f-
dc.subject.meshturgoderm oc-
dc.subject.meshciprofloxacin-
dc.subject.meshclioquinol-
dc.subject.meshclobetasol propionate-
dc.subject.meshclobetasol propionate/tp [Topical Drug Administration]-
dc.subject.meshclobetasone-
dc.subject.meshclobetasone/tp [Topical Drug Administration]-
dc.subject.meshclotrimazole-
dc.subject.meshflumetasone acetate-
dc.subject.meshacne-
dc.subject.meshbehavior-
dc.subject.meshdermatology-
dc.subject.meshdiabetes mellitus-
dc.subject.meshdrug cost-
dc.titleMagnitude, characteristics and consequences of topical steroid misuse in rural North India: An observational study among dermatology outpatients.en
dc.typeArticleen
dc.identifier.affiliationDermatology-
dc.type.studyortrialObservational study (cohort, case-control, cross sectional or survey)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1136/bmjopen-2019-032829-
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid32430446 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32430446]en
dc.identifier.source631807724en
dc.identifier.institution(Thomas) Department of Dermatology, Herbertpur Christian Hospital, Dehradun, Uttarakahnd, India (Wong) Department of Dermatology, Monash Medical Centre, Melbourne, VIC, Australia (Wong) Department of Dermatology, Royal Melbourne Hospital, Melbourne, VIC, Australia (Anderson, Grills) Nossal Institute for Global Health, School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia (Grills) Australia India Institute, University of Melbourne, Melbourne, VIC, Australiaen
dc.description.addressM. Thomas, Department of Dermatology, Herbertpur Christian Hospital, Dehradun, Uttarakahnd, India. E-mail: vijuandmolly@gmail.comen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2020 Elsevier B.V., All rights reserved.en
dc.subect.keywordsinfective misuse rural tinea topical steroiden
dc.identifier.authoremailThomas M.; vijuandmolly@gmail.comen
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairetypeArticle-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:Articles
Show simple item record

Page view(s)

64
checked on Feb 11, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.